XML 21 R11.htm IDEA: XBRL DOCUMENT v3.23.3
REVENUES
 9 Months Ended
Sep. 30, 2023
Revenue from Contract with Customer [Abstract]  
REVENUES REVENUES
Disaggregation of Revenues
The following table summarizes our Total revenues:
Three Months Ended September 30, 2023Three Months Ended September 30, 2022
(in millions)U.S.EuropeOther InternationalTotalU.S.EuropeOther InternationalTotal
Product sales:
HIV
Biktarvy$2,504 $313 $268 $3,085 $2,286 $278 $201 $2,766 
Complera/Eviplera13 18 3 34 20 21 3 43 
Descovy460 25 26 511 444 28 28 500 
Genvoya433 47 23 503 502 71 27 600 
Odefsey257 74 11 343 276 86 12 374 
Stribild18 5 2 25 22 7 3 32 
Truvada15 3 4 22 24 3 2 30 
Revenue share - Symtuza(1)
96 32 3 131 85 40 4 130 
Other HIV(2)
10 3 — 13 1 6 5 12 
Total HIV3,807 519 341 4,667 3,661 541 285 4,487 
Oncology
Cell Therapy
Tecartus64 27 4 96 60 20 1 81 
Yescarta197 154 40 391 210 91 16 317 
Total Cell Therapy261 181 45 486 270 111 17 398 
Trodelvy201 62 21 283 139 38 3 180 
Total Oncology462 243 65 769 409 149 20 578 
Liver Disease
Chronic hepatitis C virus (“HCV”)
Ledipasvir/Sofosbuvir(3)
17 2 4 23 8 5 12 25 
Sofosbuvir/Velpatasvir(4)
215 76 85 377 241 131 84 455 
Other HCV(5)
28 7 3 38 34 7 2 44 
Total HCV260 85 93 438 283 143 98 524 
Chronic hepatitis B virus (“HBV”) / Chronic hepatitis delta virus (“HDV”)
Vemlidy112 9 106 228 129 9 90 228 
Viread4 5 12 21 2 5 15 22 
Other HBV/HDV(6)
— 19 — 20 — 13 — 14 
Total HBV/HDV116 34 119 269 131 28 106 264 
Total Liver Disease376 119 211 706 413 170 204 788 
Veklury258 65 313 636 336 130 458 925 
Other
AmBisome12 63 39 115 9 63 33 105 
Letairis36 — — 36 43 — — 43 
Other(7)
34 9 23 65 28 11 13 52 
Total Other82 72 62 216 80 75 46 200 
Total product sales4,985 1,017 992 6,994 4,900 1,064 1,013 6,978 
Royalty, contract and other revenues32 23 1 56 28 37 — 64 
Total revenues$5,017 $1,040 $993 $7,051 $4,928 $1,101 $1,013 $7,042 
Nine Months Ended September 30, 2023Nine Months Ended September 30, 2022
(in millions)U.S.EuropeOther InternationalTotalU.S.EuropeOther InternationalTotal
Product sales:
HIV
Biktarvy$7,104 $920 $717 $8,741 $6,088 $807 $577 $7,472 
Complera/Eviplera40 55 9 104 56 76 10 142 
Descovy1,314 75 86 1,475 1,152 92 91 1,335 
Genvoya1,305 157 81 1,544 1,441 220 103 1,764 
Odefsey754 223 33 1,011 763 278 36 1,077 
Stribild57 16 6 79 68 23 7 98 
Truvada71 10 16 97 77 12 13 102 
Revenue share - Symtuza(1)
278 101 10 390 251 126 10 388 
Other HIV(2)
24 11 6 41 11 20 15 45 
Total HIV10,949 1,568 965 13,482 9,906 1,653 863 12,422 
Oncology
Cell Therapy
Tecartus179 83 11 272 160 56 2 217 
Yescarta624 408 99 1,130 528 253 42 823 
Total Cell Therapy802 491 109 1,402 688 308 44 1,040 
Trodelvy551 169 44 764 379 98 8 485 
Total Oncology1,354 660 153 2,167 1,067 407 52 1,525 
Liver Disease
HCV
Ledipasvir/Sofosbuvir(3)
29 11 14 54 27 13 43 83 
Sofosbuvir/Velpatasvir(4)
643 250 266 1,159 629 288 244 1,161 
Other HCV(5)
80 33 10 123 88 31 7 127 
Total HCV751 294 289 1,335 745 332 294 1,371 
HBV/HDV
Vemlidy295 28 322 645 306 27 289 622 
Viread4 17 40 62 4 17 48 69 
Other HBV/HDV(6)
— 50 — 51 1 41 — 42 
Total HBV/HDV299 96 363 758 311 85 337 733 
Total Liver Disease1,051 390 652 2,093 1,056 417 631 2,104 
Veklury607 227 630 1,465 1,179 560 1,166 2,905 
Other
AmBisome39 192 150 381 48 192 140 380 
Letairis106 — — 106 135 — — 135 
Other(7)
91 31 49 171 91 52 35 178 
Total Other236 224 199 658 275 244 174 693 
Total product sales14,196 3,069 2,599 19,864 13,482 3,281 2,887 19,650 
Royalty, contract and other revenues57 77 4 138 140 98 4 242 
Total revenues$14,253 $3,146 $2,603 $20,002 $13,622 $3,378 $2,891 $19,892 
_______________________________
(1)    Represents our revenue from cobicistat (“C”), emtricitabine (“FTC”) and tenofovir alafenamide (“TAF”) in Symtuza (darunavir/C/FTC/TAF), a fixed dose combination product commercialized by Janssen Sciences Ireland Unlimited Company (“Janssen”).
(2)    Includes Atripla, Emtriva, Sunlenca and Tybost.
(3)    Amounts consist of sales of Harvoni and the authorized generic version of Harvoni sold by our separate subsidiary, Asegua Therapeutics LLC.
(4)    Amounts consist of sales of Epclusa and the authorized generic version of Epclusa sold by our separate subsidiary, Asegua Therapeutics LLC.
(5)    Includes Vosevi and Sovaldi.
(6)    Includes Hepcludex and Hepsera.
(7)    Includes Cayston, Jyseleca, Ranexa and Zydelig.
Revenues from Major Customers
The following table summarizes revenues from each of our customers who individually accounted for 10% or more of our Total revenues:
 Three Months EndedNine Months Ended
September 30,September 30,
(as a percentage of total revenues)2023202220232022
Cencora, Inc. (formerly known as AmerisourceBergen Corporation)
19 %18 %19 %17 %
Cardinal Health, Inc.25 %25 %26 %25 %
McKesson Corporation22 %22 %21 %20 %
Revenues Recognized from Performance Obligations Satisfied in Prior Years
The following table summarizes revenues recognized from performance obligations satisfied in prior years:
Three Months EndedNine Months Ended
September 30,September 30,
(in millions)2023202220232022
Revenue share with Janssen and royalties for licenses of intellectual property$166 $192 $517 $573 
Changes in estimates$111 $207 $347 $452 
Contract Balances
The following table summarizes our contract balances:
(in millions)September 30, 2023December 31, 2022
Contract assets(1)
$123 $171 
Contract liabilities(2)
$68 $102 
________________________________
(1)    Consists of unbilled amounts primarily from arrangements where the licensing of intellectual property is the only or predominant performance obligation.
(2)    Generally results from receipt of advance payment before our performance under the contract.